Vaccination of Alzheimer's model mice with Aβ derivative in alum adjuvant reduces Aβ burden without microhemorrhages
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Immunotherapy holds great promise for Alzheimer's disease (AD) and other conformational disorders but certain adverse reactions need to be overcome. The meningoencephalitis observed in the first AD vaccination trial was likely related to excessive cell‐mediated immunity caused by the immunogen, amyloid‐β (Aβ) 1–42, and the adjuvant, QS−21. To avoid this toxicity, we have been using Aβ derivatives in alum adjuvant that promotes humoral immunity. Other potential side effects of immunotherapy are increased vascular amyloid and associated microhemorrhages that may be related to rapid clearance of parenchymal amyloid. Here, we determined if our immunization strategy was associated with this form of toxicity, and if the therapeutic effect was age‐dependent. Tg2576 mice and wild‐type littermates were immunized from 11 or 19 months and their behaviour evaluated prior to killing at 24 months. Subsequently, plaque‐ and vascular‐Aβ burden, Aβ levels and associated pathology was assessed. The therapy started at the cusp of amyloidosis reduced cortical Aβ deposit burden by 31% and Aβ levels by 30–37%, which was associated with cognitive improvements. In contrast, treatment from 19 months, when pathology is well established, was not immunogenic and therefore did not reduce Aβ burden or improve cognition. Significantly, the immunotherapy in the 11–24 months treatment group, that reduced Aβ burden, did not increase cerebral bleeding or vascular Aβ deposits in contrast to several Aβ antibody studies. These findings indicate that our approach age‐dependently improves cognition and reduces Aβ burden when used with an adjuvant suitable for humans, without increasing vascular Aβ deposits or microhemorrhages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 3×
“In the three autopsy cases from the clinical trial, extensive vascular Ab remained despite parenchymal Ab clearance, and one of these individuals had numerous brain microhemorrhages (Nicoll et al., 2003; Ferrer et al., 2004; Masliah et al., 2005).”
BackgroundClinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053 · cited 2×
“These mice show rapid increases in Ab levels at approximately 6 months of age with Ab deposition developing in the following months although extensive amyloid burden is usually not observed until the animals are well into their second year (Kawarabayashi et al., 2001).”
BackgroundImmunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858 · cited 2×
“Journal Compilation ª Federation of European Neuroscience Societies and Blackwell Publishing Ltd European Journal of Neuroscience, 24, 2530–2542 Ab (Janus et al., 2000; Morgan et al., 2000; Dodart et al., 2002; Kotilinek et al., 2002; Sigurdsson et al., 2004; Jensen et al., 2005).”
BackgroundCerebral Hemorrhage After Passive Anti-Aβ Immunotherapy
Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., Mathews, P. M., & Jucker, M. (2002) · Science · doi:10.1126/science.1078259 · Cited by 511
Reversible memory loss in a mouse transgenic model of Alzheimer’s disease
Kotilinek, L. A., Bacskai, B., Westerman, M., Kawarabayashi, T., Younkin, L., Hyman, B. T., Younkin, S., & Ashe, K. H. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06331.2002 · Cited by 420 · cited 3×
“Journal Compilation ª Federation of European Neuroscience Societies and Blackwell Publishing Ltd European Journal of Neuroscience, 24, 2530–2542 Ab (Janus et al., 2000; Morgan et al., 2000; Dodart et al., 2002; Kotilinek et al., 2002; Sigurdsson et al., 2004; Jensen et al., 2005).”
BackgroundRacke, M. M., Boone, L. I., Hepburn, D. L., Parsadainian, M., Bryan, M. T., Ness, D. K., Piroozi, K. S., Jordan, W. H., Brown, D. D., Hoffman, W. P., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4337-04.2005 · Cited by 320
Sadowski, M., Pankiewicz, J., Scholtzova, H., Ripellino, J. A., Li, Y., Schmidt, S. D., Mathews, P. M., Fryer, J. D., Holtzman, D. M., Sigurdsson, E. M., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63355-x · Cited by 154 · cited 1×
“Staining was performed as described previously (Sadowski et al., 2004; Sigurdsson et al., 2004).”
Self-citation
Research works printed but not linked: 40
- 10.1177/42.8.8027523 · DOI · Paper page
- 10.4049/jimmunol.174.3.1580 · DOI · Paper page
- 10.1212/01.WNL.0000150527.24596.29 · DOI
- 10.1523/JNEUROSCI.19-08-03248.1999 · DOI · Paper page
- 10.1002/jnr.10721 · DOI · Paper page
- 10.1016/S0197-4580(01)00245-7 · DOI
- 10.3758/BF03211017 · DOI
- 10.1111/j.1750-3639.2004.tb00493.x · DOI · Paper page
- 10.1073/pnas.0404866101 · DOI · Paper page
- 10.1016/S0169-409X(98)00008-8 · DOI · Paper page
- 10.1080/00221309.1946.10544520 · DOI · Paper page
- 10.1016/S0896-6273(03)00294-0 · DOI · Paper page
- 10.1126/science.274.5284.99 · DOI · Paper page
- 10.1002/1098-2302(2001)38:1<33::AID-DEV3>3.0.CO;2-0 · DOI
- Jameson B.A., 1988, The antigenic index: a novel algorithm for predicting antigenic determinants, Comput. Appl. Biosci., 4, 181
- 10.1016/j.neuroscience.2004.09.055 · DOI
- Kim K.S., 1990, Detection and quantification of amyloid β‐peptide with 2 monoclonal antibodies, Neurosci. Res. Comm., 7, 113
- 10.1002/ana.20009 · DOI · Paper page
- 10.1016/j.febslet.2005.03.070 · DOI · Paper page
- 10.1023/A:1023203122036 · DOI
- 10.1172/JCI25410 · DOI · Paper page
- 10.1212/01.WNL.0000148590.39911.DF · DOI · Paper page
- 10.1038/35050116 · DOI · Paper page
- 10.1037/h0083542 · DOI · Paper page
- Schmidt S.D., 2005, Amyloid Proteins: Methods and Protocols, 267
- Schmidt S.D., 2005, Amyloid Proteins: Methods and Protocols, 279
- Scholtzova H., 2002, Safety of potential vaccines for Alzheimer's disease, Soc. Neurosci. Abstr, 227.1
- 10.3758/CABN.1.1.83 · DOI
- Sigurdsson E.M., 2005, Histological staining of amyloid‐β in mouse brains, Meth. Mol. Biol., 299, 299
- 10.2174/138161206777698837 · DOI · Paper page
- Sigurdsson E.M., 2006, A non‐toxic ligand for voxel‐based MRI analysis of plaques in AD transgenic mice, Neurobiol. Aging
- 10.1523/JNEUROSCI.1344-04.2004 · DOI · Paper page
- 10.1016/S0197-4580(96)00169-8 · DOI
- 10.1016/S0002-9440(10)61715-4 · DOI · Paper page
- 10.1016/0306-4522(94)90010-8 · DOI · Paper page
- 10.1002/mrm.10529 · DOI · Paper page
- 10.1111/j.0105-2896.2005.00264.x · DOI · Paper page
- 10.1016/S0166-2236(98)01362-9 · DOI · Paper page
- 10.1186/1742-2094-1-24 · DOI
- 10.1111/j.1750-3639.2005.tb00102.x · DOI · Paper page
Cited by
Castellani, R. J., Rolston, R. K., & Smith, M. A. (2010) · Disease-a-Month · doi:10.1016/j.disamonth.2010.06.001 · Cited by 519
Asuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506
“…that autoantibodies increase with age, and we have observed a similar phenomenon in the Tg2576 mouse model of cerebral A amyloidosis although those animals are usually well into their second year when appreciable levels of autoantibodies are detected (Sigurdsson et al., 2004; Asuni et al., 2006).”
BackgroundMethodSelf-citationComparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
Petrovsky, N. (2015) · Drug Safety · doi:10.1007/s40264-015-0350-4 · Cited by 366
Boutajangout, A., Ingadottir, J., Davies, P., & Sigurdsson, E. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07337.x · Cited by 306
Self-citationImmunotherapeutic Approaches for Alzheimer’s Disease
Wisniewski, T., & Goñi, F. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.064 · Cited by 284
Metadata
- Authors
- Asuni, A. A., Boutajangout, A., Scholtzova, H., Knudsen, E., Li, Y. S., Quartermain, D., Frangione, B., Wisniewski, T., & Sigurdsson, E. M.
- Venue
- European Journal of Neuroscience
- Publisher
- Wiley
- Published
- 2006-11
- Volume
- 24
- Issue
- 9
- Pages
- 2530-2542
- ISSN
- 0953-816X (ISSN-L)
- 1460-9568
- OpenAlex
- W1529100127
- Cited by
- 91
- References
- 10
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vaccination of Alzheimer's model mice with Aβ derivative in alum adjuvant reduces Aβ burden without microhemorrhages. https://app.cochat.ai/papers/10.1111/j.1460-9568.2006.05149.x
- The paper
- Asuni, A. A., Boutajangout, A., Scholtzova, H., Knudsen, E., Li, Y. S., Quartermain, D., Frangione, B., Wisniewski, T., & Sigurdsson, E. M. (2006). Vaccination of Alzheimer's model mice with Aβ derivative in alum adjuvant reduces Aβ burden without microhemorrhages. European Journal of Neuroscience. https://doi.org/10.1111/j.1460-9568.2006.05149.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.